AGING AND HUMAN ENDOCRINE REGULATION

我们研究了12名65岁以上的健康男性的睡眠和夜间睡眠 GH分泌谱，以及葡萄糖耐量，IGF-I，T， 骨钙素、血脂和骨生化（尿吡啶酚 交联和钙），身体成分，肌肉力量和 通过NMR利用高能磷酸盐，所有这些都在 GHRH 1-29自身皮下注射方案，每晚一次，持续6周。那里 注射GHRH后GH分泌显著增加，平均 血清IGF-I水平和肌肉力量显著降低， 葡萄糖耐量曲线下面积和LDL胆固醇，但无变化 在甘油三酯或HDL胆固醇中，治疗对 体重指数、其他人体测量或骨骼测量 新陈代谢.对160名男性进行了为期6个月的治疗， 女性>65岁，使用rhGH，性类固醇，两者都用，或两者都不用， 相关的临床和生理终点已经启动， 日至今

We studied 12 healthy men >65 years old overnight for sleep and nocturnal GH secretory profiles, as well as for glucose tolerance,IGF-I,T, osteocalcin, lipid profiles, and bone biochemistries (urine pyridinoline cross-links, and calcium), body composition, muscle strength and utilization of high energy phosphate by NMR, all before and at the end of a regimen of GHRH 1-29 self-injected sc once nightly for 6 weeks. There was a significant increase in GH secretion after GHRH injections, in mean serum IGF-I levels, and in muscle strength and significant decreases in area under glucose tolerance curves and in LDL cholesterol, but no changes in triglycerides or HDL cholesterol and no apparent effect of treatment on body mass index, other anthropometric measures or measures of bone metabolism. A study of the effects of 6 months of treatment of 160 men and women >65 years with rhGH, sex steroid, both, or neither on multiple relevant clinical and physiologic end-points has been initiated and is ongoing.